JP7862402B2 - リジニラゾールの固形錠剤剤形 - Google Patents

リジニラゾールの固形錠剤剤形

Info

Publication number
JP7862402B2
JP7862402B2 JP2023542844A JP2023542844A JP7862402B2 JP 7862402 B2 JP7862402 B2 JP 7862402B2 JP 2023542844 A JP2023542844 A JP 2023542844A JP 2023542844 A JP2023542844 A JP 2023542844A JP 7862402 B2 JP7862402 B2 JP 7862402B2
Authority
JP
Japan
Prior art keywords
tablet
lysinirazole
present
formulation according
tetrahydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023542844A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024503689A5 (cg-RX-API-DMAC7.html
JP2024503689A (ja
Inventor
エックス. ウィルソン,フランシス
トレスピディ,ローラ
カルニオー,ジャン-フランソワ
ティミンズ,ピーター
Original Assignee
サミット (オックスフォード) リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サミット (オックスフォード) リミティド filed Critical サミット (オックスフォード) リミティド
Publication of JP2024503689A publication Critical patent/JP2024503689A/ja
Publication of JP2024503689A5 publication Critical patent/JP2024503689A5/ja
Application granted granted Critical
Publication of JP7862402B2 publication Critical patent/JP7862402B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023542844A 2021-01-14 2022-01-14 リジニラゾールの固形錠剤剤形 Active JP7862402B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2100470.0A GB202100470D0 (en) 2021-01-14 2021-01-14 Solid tablet dosage for of ridinilazole
GB2100470.0 2021-01-14
PCT/IB2022/050311 WO2022153246A1 (en) 2021-01-14 2022-01-14 Solid tablet dosage form of ridinilazole

Publications (3)

Publication Number Publication Date
JP2024503689A JP2024503689A (ja) 2024-01-26
JP2024503689A5 JP2024503689A5 (cg-RX-API-DMAC7.html) 2026-04-02
JP7862402B2 true JP7862402B2 (ja) 2026-05-19

Family

ID=74679044

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023542844A Active JP7862402B2 (ja) 2021-01-14 2022-01-14 リジニラゾールの固形錠剤剤形

Country Status (12)

Country Link
US (1) US12318487B2 (cg-RX-API-DMAC7.html)
EP (1) EP4277604A1 (cg-RX-API-DMAC7.html)
JP (1) JP7862402B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230131253A (cg-RX-API-DMAC7.html)
CN (1) CN116801867A (cg-RX-API-DMAC7.html)
AU (1) AU2022207756B2 (cg-RX-API-DMAC7.html)
CA (1) CA3145677A1 (cg-RX-API-DMAC7.html)
GB (1) GB202100470D0 (cg-RX-API-DMAC7.html)
IL (1) IL304354A (cg-RX-API-DMAC7.html)
MX (1) MX2023008249A (cg-RX-API-DMAC7.html)
WO (1) WO2022153246A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202306739B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023213878A1 (en) * 2022-05-04 2023-11-09 Summit (Oxford) Limited Solid tablet dosage form of ridinilazole

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017048217A (ja) 2008-12-02 2017-03-09 サミット (オックスフォード) リミテッド 抗細菌化合物
WO2020017666A1 (en) 2018-07-19 2020-01-23 Takeda Pharmaceutical Company Limited Pharmaceutical compositions with a cdc7 inhibitor
JP2020518565A (ja) 2017-04-28 2020-06-25 アサナ バイオサイエンシズ,リミティド ライアビリティ カンパニー アトピー性皮膚炎の治療及び原薬の安定性を向上するための製剤、方法、キット、及び剤形
US20200290995A1 (en) 2017-10-05 2020-09-17 Sandoz Ag Process for the Preparation of Crystalline Ridinilazole Using Acid Addition Salts

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3696495A (en) 1994-11-17 1996-06-17 F. Hoffmann-La Roche Ag Antibacterial dibenzimidazole derivatives
PL362691A1 (en) 2000-12-15 2004-11-02 Vertex Pharmaceuticals Incorporated Bacterial gyrase inhibitors and uses thereof
AU2003245442B2 (en) 2002-06-13 2009-02-05 Vertex Pharmaceuticals Incorporated 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase IV inhibitors for the treatment of bacterial infections
EP1558341A4 (en) 2002-11-01 2010-09-08 Paratek Pharm Innc TRANSCRIPTION FACTOR MODULATING CONNECTIONS AND THEIR USE
EP1742637A4 (en) 2004-04-23 2011-06-08 Paratek Pharm Innc TRANSCRIPTION FACTOR MODULATION COMPOUNDS AND METHODS OF USE
US7825154B2 (en) 2005-08-12 2010-11-02 The United States Of America As Represented By The Secretary Of The Army Small molecule inhibitors of botulinum neurotoxins
WO2007056330A1 (en) 2005-11-07 2007-05-18 Vertex Pharmaceuticals Incorporated Benzimidazole derivatives as gyrase inhibitors
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
CA2563690C (en) 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
FR2918566B1 (fr) * 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
CN102711739B (zh) * 2009-11-13 2015-12-16 阿斯利康(瑞典)有限公司 双层片剂
CA2801274C (en) 2010-06-01 2021-06-15 Summit Corporation Plc Compounds for the treatment of clostridium difficile-associated disease
WO2011151620A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
KR102631986B1 (ko) * 2015-01-27 2024-01-30 얀센 파마슈티카 엔브이 분산성 조성물
JP7730803B2 (ja) 2019-07-17 2025-08-28 サミット (オックスフォード) リミティド リジニラゾールの調製方法およびその結晶形態

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017048217A (ja) 2008-12-02 2017-03-09 サミット (オックスフォード) リミテッド 抗細菌化合物
JP2020518565A (ja) 2017-04-28 2020-06-25 アサナ バイオサイエンシズ,リミティド ライアビリティ カンパニー アトピー性皮膚炎の治療及び原薬の安定性を向上するための製剤、方法、キット、及び剤形
US20200290995A1 (en) 2017-10-05 2020-09-17 Sandoz Ag Process for the Preparation of Crystalline Ridinilazole Using Acid Addition Salts
WO2020017666A1 (en) 2018-07-19 2020-01-23 Takeda Pharmaceutical Company Limited Pharmaceutical compositions with a cdc7 inhibitor

Also Published As

Publication number Publication date
WO2022153246A1 (en) 2022-07-21
ZA202306739B (en) 2025-05-28
US20220226249A1 (en) 2022-07-21
CN116801867A (zh) 2023-09-22
EP4277604A1 (en) 2023-11-22
GB202100470D0 (en) 2021-03-03
MX2023008249A (es) 2023-07-26
CA3145677A1 (en) 2022-07-14
AU2022207756A9 (en) 2024-05-09
US12318487B2 (en) 2025-06-03
AU2022207756B2 (en) 2026-01-15
AU2022207756A1 (en) 2023-07-27
KR20230131253A (ko) 2023-09-12
JP2024503689A (ja) 2024-01-26
IL304354A (en) 2023-09-01

Similar Documents

Publication Publication Date Title
JP5632367B2 (ja) Bibw2992を含有する固形医薬製剤
KR101849808B1 (ko) 난용성 약물의 용해성 개선 제제
AU2011316003B2 (en) Pharmaceutical compositions containing a DGAT1 inhibitor
AU2017215530B2 (en) Galenic formulations of organic compounds
WO2010027921A1 (en) Co-crystals and pharmaceutical formulations comprising the same
CA2904032C (en) Formulations of organic compounds
JP2009542647A (ja) メマンチン医薬組成物
CA2815280C (en) A composition comprising s-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate and croscarmellose sodium
US12318487B2 (en) Solid tablet dosage form of ridinilazole
WO2023213878A1 (en) Solid tablet dosage form of ridinilazole
KR20110063684A (ko) 알리스키렌을 포함하는 생약 제형 및 용융 압출 과립화에 의한 그의 제조 방법
CN109963565B (zh) 一种药物组合物及其制备方法
WO2024079245A1 (en) Ridinilazole for treating clostridium difficile
TW202435886A (zh) 米爾維仙(milvexian)醫藥組合物
AU2024317636A1 (en) Pharmaceutical composition containing substituted indol-5-ol derivative and use thereof
WO2019030773A1 (en) DICLOFENAC COMPOSITIONS WITH LOW DOSE
HK1226312A1 (en) A composition comprising s-[2-( [ [1-(2-ethylbutyl) -cyclohexyl] -carbonyl]amino)phenyl] 2-thylpropanethioate and croscarmellosesodium

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260212

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20260325

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260407

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260507

R150 Certificate of patent or registration of utility model

Ref document number: 7862402

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150